ArticleJournal of virology2025
A novel antiviral role of ankyrin repeat and LEM domain-containing 2 (ANKLE2) in restricting vaccinia virus through barrier to autointegration factor (BAF).
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sequence and structural alignments reveal insights into ANKLE2 evolution and function.Protein science : a publication of the Protein Society · 2026Article
- Barrier-to-Autointegration Factor 1: a key regulator of nuclear envelope integrity, genome stability, and disease progression.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
ANKLE2 (Ankyrin repeat and LEM domain-containing protein 2) is an emerging host factor with previously undefined roles in antiviral defense. Here, we show that ANKLE2 can exert robust antiviral activity against vaccinia virus by regulating the phosphorylation status of barrier-to-autointegration factor (BAF), a ubiquitous DNA-binding protein that compacts DNA and restricts viral replication. We first demonstrate that depletion of endogenous ANKLE2 increased BAF phosphorylation and rescued replication of B1-knockout vaccinia virus, whereas reconstitution restored restriction. We then perform domain-mapping experiments of ANKLE2, revealing that its LEM domain and Caulimovirus domain (CD domain) are essential for BAF dephosphorylation, ANKLE2-BAF association, and/or antipoxviral activity, whereas the transmembrane (TM) domain restricts cytoplasmic redistribution and functions as a negative regulator. Together, these findings uncover a previously unrecognized host defense pathway against poxviruses, provide new insight into how host ANKLE2 proteins coordinate antiviral responses, and reveal a novel antiviral role for ANKLE2 in limiting vaccinia virus DNA replication and progeny release through regulation of BAF phosphorylation.IMPORTANCEVaccinia virus relies on disabling host defenses to replicate efficiently, with the host DNA-binding protein BAF representing a key target for viral kinases. Here, we uncover ANKLE2 as a critical host factor that counteracts vaccinia virus by sustaining the antiviral activity of BAF. ANKLE2 promotes BAF dephosphorylation, thereby preventing viral escape from BAF-mediated restriction. Our results reveal that distinct domains of ANKLE2 differentially regulate its antiviral activity, with the LEM and CD domains promoting BAF dephosphorylation and antiviral activity, and the transmembrane domain acting as a negative regulator by limiting cytoplasmic redistribution. These findings highlight ANKLE2 as a domain-dependent regulator of host defense and expand our understanding of the molecular circuitry that controls poxvirus replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.